Bioharvest Sciences (BHST) EBIT (2023 - 2025)

Bioharvest Sciences' EBIT history runs 3 years deep, the most recent figure standing at -$1.1 million for Q4 2025.

• On a quarterly basis, EBIT rose 33.55% year-over-year to -$1.1 million in Q4 2025; TTM through Dec 2025 was -$5.6 million, a 20.23% increase from a year earlier, with the FY2025 full-year figure at -$5.6 million, up 20.23% from the prior year.
• EBIT retreated to -$1.1 million in Q4 2025 per BHST's latest filing, from -$920000.0 in the prior quarter.
• Across five years, EBIT topped out at $2.9 million in Q2 2023 and bottomed at -$17.4 million in Q4 2023.
• The 3-year median for EBIT is -$1.7 million (2024), against an average of -$2.3 million.
• Biggest YoY gain for EBIT was 90.3% in 2024; the steepest drop was 204.73% in 2024.
• Year by year, EBIT stood at -$17.4 million in 2023, then jumped by 90.3% to -$1.7 million in 2024, then soared by 33.55% to -$1.1 million in 2025.
• Per Business Quant, the three latest BHST EBIT figures stand at -$1.1 million (Q4 2025), -$920000.0 (Q3 2025), and -$1.8 million (Q2 2025).